8-K: Reviva Achieves Key Brilaroxazine Milestones

Reviva Pharmaceuticals reports successful completion of its Phase 3 OLE trial for brilaroxazine, targeting Q2 2026 NDA submission for schizophrenia.

Summary

• Reviva Pharmaceuticals Holdings, Inc. reported financial results for the second quarter ended June 30, 2025, and summarized recent business highlights.
• The company successfully completed its Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine in schizophrenia.
• Brilaroxazine demonstrated a well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year, including improvements in PANSS total score (-18.1), positive symptoms (-5.0), negative symptoms (-4.4), and negative Marder factor (-4.4).
• The discontinuation rate for brilaroxazine in the OLE study was 35% after 1-year for pooled doses (15, 30, and 50 mg, N=446).
• All key clinical data required for a New Drug Application (NDA) are believed to be completed.
• A meeting with the FDA is planned for Q4 2025 to discuss brilaroxazine's path to approval for schizophrenia.
• A potential NDA submission for brilaroxazine in schizophrenia is targeted for Q2 2026, pending favorable FDA feedback and excluding the planned Phase 3 RECOVER-2 trial.
• The company reported a net loss of approximately $6.1 million, or $0.12 per share, for Q2 2025, compared to a net loss of $7.9 million, or $0.26 per share, for Q2 2024.
• Cash and cash equivalents totaled approximately $10.4 million as of June 30, 2025, down from $13.5 million as of December 31, 2024.
• Reviva completed a public equity offering, raising gross proceeds of $10.0 million.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful completion of a pivotal Phase 3 OLE trial with strong efficacy and safety data, a clear regulatory path with a planned FDA meeting and targeted NDA submission, and a reduction in net loss. The recent capital raise also provides financial stability. While cash burn continues, it is typical for a development-stage biotech, and the clinical progress outweighs this in terms of immediate sentiment.

Positives

• Successful completion of the Phase 3 RECOVER open-label extension (OLE) 1-year study for brilaroxazine, a major clinical milestone.
• Brilaroxazine demonstrated a well-tolerated safety profile and sustained broad-spectrum efficacy over 1-year across all symptom domains in schizophrenia patients.
• Significant improvements observed in PANSS total score (-18.1), positive symptoms (-5.0), negative symptoms (-4.4), and negative Marder factor (-4.4).
• All key clinical data required for NDA submission are considered complete, streamlining the regulatory pathway.
• Planned meeting with the FDA in Q4 2025 to discuss approval path, indicating clear regulatory engagement.
• Targeted NDA submission for brilaroxazine in Q2 2026, offering a defined timeline for potential market entry.
• Net loss decreased to $6.1 million in Q2 2025 from $7.9 million in Q2 2024, indicating improved financial performance.
• Completed a public equity offering, raising $10.0 million in gross proceeds, strengthening the cash position.
• Continuing efforts to expand a strong diversified patent portfolio, potentially extending market exclusivity up to 2045 and beyond.

Negatives

• The company continues to operate at a net loss, reporting approximately $6.1 million for Q2 2025.
• Cash and cash equivalents decreased to $10.4 million as of June 30, 2025, from $13.5 million as of December 31, 2024, indicating ongoing cash burn.
• NDA submission is contingent on 'favorable feedback from the FDA', introducing an element of regulatory uncertainty.
• Plans for a potential registrational Phase 3 RECOVER-2 trial are being assessed and are 'pending FDA recommendation', suggesting a possible requirement for additional trials before approval.

Risks

• Regulatory approval risk: The potential NDA submission is targeted for Q2 2026 and is contingent on favorable feedback from the FDA regarding the current data package, meaning approval is not guaranteed and additional trials (like RECOVER-2) might be required.
• Clinical trial risk: While the OLE trial was successful, future trials, such as the potential registrational Phase 3 RECOVER-2 trial, may not yield similar positive results or may face unforeseen challenges.
• Funding risk: Despite a recent capital raise, the company continues to incur net losses and burn cash, indicating a potential need for further capital raises to fund ongoing operations and clinical development.
• Market competition: Brilaroxazine aims to be a 'new standard of care' in schizophrenia, but the market for CNS therapies is competitive, and adoption may be challenging.
• Intellectual property risk: While the company is expanding its patent portfolio, there is always a risk of patent challenges or expiration that could impact market exclusivity.

Future Outlook

Reviva Pharmaceuticals plans a meeting with the FDA in Q4 2025 to discuss the approval pathway for brilaroxazine in schizophrenia. A New Drug Application (NDA) submission is targeted for Q2 2026, contingent on favorable FDA feedback and based on the current data package, potentially excluding a planned Phase 3 RECOVER-2 trial. The company is also assessing plans to initiate the RECOVER-2 trial if recommended by the FDA. An Investigational New Drug (IND) submission for a liposomal-gel formulation of brilaroxazine in psoriasis is expected by Q2 2026. The company is actively pursuing partnership opportunities for pipeline development.

Management Comments

• "The successful completion of our global OLE 1-year trial marks a major milestone for the brilaroxazine program as we advance toward potential registration."
• "This comprehensive dataset reinforces our prior positive clinical results and highlights the long-term safety, broad-spectrum sustained efficacy, and strong adherence profile of once daily brilaroxazine."
• "We believe all key clinical data required for NDA are completed and we are preparing for an End-of-Phase 3 meeting with the FDA planned in the fourth quarter of the year to discuss our future NDA submission based on the current data package and excluding the planned Phase 3 RECOVER-2 trial."
• "Pending favorable feedback from the FDA, we will target an NDA submission in the second quarter of 2026."
• "Brilaroxazine continues to demonstrate a differentiated and durable clinical profile, positioning it as a potential new standard of care in schizophrenia and a meaningful driver of long-term value."

Industry Context

This announcement positions Reviva's brilaroxazine as a promising late-stage candidate in the central nervous system (CNS) therapeutic area, specifically for schizophrenia. The sustained broad-spectrum efficacy, including positive and negative symptoms, and a well-tolerated safety profile, could differentiate it in a market with significant unmet needs, particularly for negative symptoms. The planned FDA meeting and targeted NDA submission indicate a clear path towards commercialization, potentially offering a new treatment option for patients and clinicians in a therapeutic area that has seen limited innovation in recent years.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess brilaroxazine's performance against global benchmarks. However, the reported efficacy across positive and negative symptoms, coupled with a favorable safety profile and 35% discontinuation rate over one year, suggests a competitive profile within the antipsychotic drug class, where long-term adherence and broad symptom control are critical challenges.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical milestones, clearer regulatory path, and reduced net loss, potentially increasing future value. The recent capital raise also dilutes existing shares but provides necessary funding.
• Patients: Potential for a new, effective, and well-tolerated treatment option for schizophrenia, addressing unmet medical needs, particularly for negative symptoms.
• Employees: Continued progress in drug development and a clearer path to market may provide job security and motivation.
• Regulatory Authorities (FDA): Engagement with the company through planned meetings indicates ongoing review and potential for a new drug approval.

Next Steps

• Planned meeting with the FDA to discuss brilaroxazine's path to approval in Q4 2025.
• Potential NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026, pending favorable FDA feedback.
• Assessment of plans to initiate a potential registrational Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia, pending FDA recommendation.
• Investigational New Drug (IND) submission for liposomal-gel formulation of brilaroxazine in psoriasis expected by Q2 2026.
• Pursuing partnership opportunities for the development of the company's pipeline.

Key Dates

Recommendation

The filing presents strong positive clinical data from a Phase 3 OLE trial for brilaroxazine, demonstrating sustained efficacy across key symptom domains and a favorable safety profile. This significantly de-risks the lead asset. The outlined regulatory pathway, including a planned FDA meeting and targeted NDA submission, provides a clear timeline for potential market entry. While the company continues to incur losses, the reduction in net loss and the recent capital raise provide a more stable financial footing. The potential for brilaroxazine to become a 'new standard of care' in schizophrenia, coupled with patent protection extending to 2045, suggests substantial long-term value creation potential for a development-stage biopharmaceutical company. The positive clinical and regulatory momentum outweighs the typical cash burn for a company at this stage.

Keywords

Reviva Pharmaceuticals, RVPH, Brilaroxazine, Schizophrenia, CNS diseases, Phase 3 trial, Open-label extension, NDA submission, FDA meeting, Biopharmaceutical, Clinical trial results, Drug development, Mental health, Psychopharmacology